The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
Georgia Karpathiou1, Celine Chauleur2, Mousa Mobarki3
1Department of Pathology, North Hospital, University Hospital of St-Etienne, France.
Background:
Evasion of immune control is a major feature of malignant tumors. This tumor aspect is poorly studied in cervical lesions.
Aim Of The Study:
To investigate the expression of PD-L1 and CTLA-4 in lesions of the uterine cervix.
Material And Methods:
Sixty-three cervical lesions from 52 patients were immunohistochemically studied. The 63 lesions included 27 invasive adenocarcinomas, 19 squamous cell carcinomas (SCCs), 7 adenocarcinomas in situ, and 10 high-grade squamous intraepithelial lesions (CIN3).
Results:
CTLA-4 and PD-L1 tumor cell expression was found in 61.5 % and 26.9 % of the invasive cases, respectively. CTLA-4 tumor cell expression and PD-L1 tumor and immune cell expression were more often found in SCCs than in adenocarcinomas. CTLA-4 tumor cell expression was more often found in advanced FIGO tumors. PD-L1 and CTLA-4 immune cell expression was associated with lymph node metastasis. CTLA-4 expression did not affect survival. The prognosis was worse for PD-L1-expressing tumors.
Conclusion:
CTLA-4 and PD-L1 are potential therapeutic targets in cervical cancer.
Related Concept Videos
Tumor Immunotherapy
Inhibition of Cdk Activity


